Sinan Gülöksüz (I.S.)

Sinan Guloksuz is an Associate Professor of Psychiatry at the Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, and the Department of Psychiatry, Specialized Treatment Early in Psychosis (STEP) Program, Yale University School of Medicine. With a background in clinical psychiatry and psychiatric epidemiology, his broader research focus has been on understanding the mechanisms underlying psychosis spectrum disorder and testing gene and environment theories at the convergence of multidimensional psychopathology in epidemiological studies. The second body of his work has been in the area of clinical trials and service research for psychotic disorders. His current research activities fall under two domains.

1. Epidemiologic research: Understanding genetic and environmental mechanisms underlying mental disorders using large population and clinical cohorts including the UK Biobank, the Netherlands Mental Health Survey and Incidence Study (NEMESIS), the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Study (EU-GEI), the Adolescent Brain Cognitive Development Study (ABCD), the Early Developmental Stages of Psychopathology Study (EDSP), the Philadelphia Neurodevelopmental Cohort, the Genetic Risk and Outcome of Psychosis  Study (GROUP), and the TwinssCan. This work involves collaboration with Profs Bart Rutten (MUMC), Jim van Os (UMCU), Michael O’Donovan (Cardiff University), Celso Arango (CIBERSAM), Robin Murray (King’s College London), and Drs Jurjen Luykx (UMCU), Margreet Ten Have (Trimbos Institute), Ron de Graaf (Trimbos Institute), and Ran Barzilay (UPenn Medicine). He is the Work-Package Leader (Gene-Environment Interaction) in the ongoing ZonMw-funded project: Outcome of Psychosis: Heterogeneity Explained by Long-lasting Individual Attributes (OPHELIA) led by Prof Iris Sommer (UMCG).

2. Clinical research: First episode psychosis research across the translational continuum involving STEP and PRIME Clinics at Yale University in the United States in collaboration with Profs. Vinod Srihari, Cenk Tek, Scott Woods, Matcheri Keshavan, and Drs Maria Ferrara, Rajiv Radhakrishnan, and Albert Powers. He is an investigator and site coordinator (Maastricht) in the ongoing ZonMw funded project, “the MEtformin-LIfestyle in Antipsychotic users trial (MELIA): optimizing the use of metformin in the management of antipsychotic-induced weight gain” led by Dr. Jurjen Luykx. He is the WorkPackage Leader (Clinical Trial) in the ongoing EU Horizon 2020 funded project: A New Intervention for Implementation of Pharmacogenetics in Psychiatry (PSY-PGx) led by Dr. Roos van Westrhenen.